Huadaein: Subsidiary isopropyl bromide ammonium inhalation aerosol received drug clinical trial approval letter

Huatdai announced that its subsidiary Dain Pharm recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The drug is called ipratropium bromide inhalation aerosol, with a dosage form of aerosol and a registration classification of Class 4 for chemical drugs. This drug is intended for the prevention and treatment of respiratory difficulties related to chronic obstructive airway diseases in children and adults; chronic obstructive bronchitis with or without emphysema; and the treatment of mild to moderate bronchial asthma. After obtaining the clinical trial approval, further clinical trials are required before the drug can be produced and marketed after being submitted for review and approval by the National Medical Products Administration.